



RealRate

PHARMACEUTICAL 2023











PHARMACEUTICAL 2023

XOMA Corp Rank 40 of 446



The relative strengths and weaknesses of XOMA Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XOMA Corp compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 51% points. The greatest weakness of XOMA Corp is the variable Other Revenues, reducing the Economic Capital Ratio by 7.3% points.

The company's Economic Capital Ratio, given in the ranking table, is 250%, being 207% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	61,253
Cost of Goods Sold	0
Intangible Assets	15,150
Liabilities, Current	6,818
Liabilities, Non-Current	0
Other Assets	63,972
Other Compr. Net Income	0
Other Expenses	82
Other Liabilities	9,550
Other Net Income	295
Other Revenues	6,027
Property and Equipment	7.0
Research and Development	153
Selling, General and Administrative Expense	23,191

Output Variable	Value in 1000 USD
Assets	140,382
Liabilities	16,368
Expenses	23,426
Revenues	6,027
Stockholders Equity	124,014
Net Income	-17,104
Comprehensive Net Income	-17,104
Economic Capital Ratio	250%

